Details for Patent: 8,357,714

Which drugs does patent 8,357,714 protect, and when does it expire?

Patent 8,357,714 protects UPNEEQ and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 8,357,714

Title:	Compositions and methods for non-surgical treatment of ptosis
Abstract:	Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
Inventor(s):	Silverberg; Mark (Santa Barbara, CA)
Assignee:	Voom, LLC (Santa Barbara, CA)
Application Number:	13/270,577
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,357,714

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rvl Pharms	UPNEEQ	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	212520-001	Jul 8, 2020		RX	Yes	Yes						METHOD OF TREATING BLEPHAROPTOSIS

International Family Members for US Patent 8,357,714

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012223615
Brazil	112013022094
Canada	2827285